U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.06 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.54 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.17
    -10.22 (-13.04%)
     
  • Gold

    1,792.30
    +8.00 (+0.45%)
     
  • Silver

    23.15
    -0.35 (-1.49%)
     
  • EUR/USD

    1.1326
    +0.0114 (+1.02%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3326
    +0.0006 (+0.04%)
     
  • USD/JPY

    113.4710
    -1.8680 (-1.62%)
     
  • BTC-USD

    54,885.25
    -36.41 (-0.07%)
     
  • CMC Crypto 200

    1,365.60
    -89.81 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.68 (-2.53%)
     

Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept, Linda Richardson, Chief Commercial Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40 a.m. ET.

A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

CONTACT

For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com